Company intelligence / Profile preview

Olymvax

Chengdu, Sichuan, Chinaen.olymvax.com ↗
Ownership
Private
Development stage
Phase 3
01

Overview

Olymvax develops and commercializes human vaccines targeting both traditional and unmet medical needs. The company has received multiple patents for its innovations and offers marketed vaccines such as those against tetanus and Hib. It continues to expand its pipeline with new vaccine candidates.

Therapeutic areas
Infectious Diseases
Modalities
VaccineBiologic
Industry
Biotech
02

Drug pipeline

7 assets

quadrivalent influenza vaccine (split virion), inactivated (MDCK cell)

3

6 more assets in the full pipeline.

Beyond the preview

Go deeper on Olymvax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Olymvax.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call